Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02443155 · ClinicalTrials.gov registry record · Phase 2
A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 308
- Enrollment target
NCT02443155 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 308 participants.
The verdict
NCT02443155, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 308 participants
- Enrollment target
Study Summary
This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes mellitus.
Interventions
- DRUG placebo
- DRUG liraglutide
- DRUG NNC0114-0006
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2015-11-10 |
| Est. Completion | 2019-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02443155
The ClinicalTrials.gov registry entry for NCT02443155 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02443155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02443155 about?
NCT02443155 is a clinical study titled "A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function". This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes mellitus.
What is the current status of trial NCT02443155?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 308 participants. The study started on 2015-11-10. Estimated completion is 2019-02-27.
What interventions are being tested in trial NCT02443155?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG), NNC0114-0006 (DRUG).
Who is sponsoring clinical trial NCT02443155?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.